NASDAQ : PLYX
Polaryx Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.86 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 92.71M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 87.23M |
| Enterprise Value | 75.69M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 14, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 49.85M |
| Shares Outstanding | 49.85M |
| Shares Change (YoY) | +13.11% |
| Shares Change (QoQ) | +2.24% |
| Owned by Insiders (%) | 30.88% |
| Owned by Institutions (%) | 4.63% |
| Float | 7.17M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.97 |
| P/TBV Ratio | 7.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.53 |
| Quick Ratio | 13.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -96.56% |
| Return on Assets (ROA) | -42.52% |
| Return on Invested Capital (ROIC) | -46.02% |
| Return on Capital Employed (ROCE) | -47.75% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$622,636 |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2.01 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 32.62 |
| Average Volume (20 Days) | 27,783 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 118,300 |
| Short Previous Month | 143,339 |
| Short % of Shares Out | 0.24% |
| Short % of Float | 1.65% |
| Short Ratio (days to cover) | 3.53 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.22M |
| Pretax Income | -6.85M |
| Net Income | -6.85M |
| EBITDA | n/a |
| EBIT | -5.22M |
| Earnings Per Share (EPS) | -$0.15 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 11.54M |
| Total Debt | n/a |
| Net Cash | 11.54M |
| Net Cash Per Share | $0.23 |
| Equity (Book Value) | 10.94M |
| Book Value Per Share | 0.22 |
| Working Capital | 10.94M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -5.81M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -5.81M |
| FCF Per Share | -$0.12 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -13.11% |
| Shareholder Yield | -13.11% |
| Earnings Yield | -8.32% |
| FCF Yield | -6.66% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.50 |
| Price Target Difference | 328.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |